HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ACRS

Aclaris Therapeutics Inc

Last Close
Mar 14 • 04:00PM ET
1.56
Dollar change
0.00
Percentage change
0.00 		%
Healthcare • Diagnostics & Research • USA • NASD
Peers: NBIX PCRX AGIO SRPT BMRN ALKS ENTA FGEN VKTX XERS
 | Held by: VTI VXF IWC DFAS ONEQ SBIO DFAC DFAU DFUS QQQS
Scroll to Statements
Index- P/E- EPS (ttm)-1.51 Insider Own15.34% Shs Outstand107.85M Perf Week-14.75%
Market Cap168.35M Forward P/E- EPS next Y-0.71 Insider Trans4.20% Shs Float91.37M Perf Month-28.11%
Income-132.06M PEG- EPS next Q-0.14 Inst Own68.59% Short Float5.22% Perf Quarter-57.02%
Sales18.72M P/S8.99 EPS this Y65.11% Inst Trans278.15% Short Ratio5.47 Perf Half Y32.20%
Book/sh1.44 P/B1.08 EPS next Y-18.99% ROA-62.91% Short Interest4.76M Perf Year27.87%
Cash/sh1.05 P/C1.48 EPS next 5Y21.55% ROE-84.46% 52W Range0.95 - 5.17 Perf YTD-37.10%
Dividend Est.- P/FCF- EPS past 5Y15.24% ROI-83.76% 52W High-69.83% Beta0.56
Dividend TTM- Quick Ratio3.99 Sales past 5Y72.53% Gross Margin17.43% 52W Low63.95% ATR (14)0.14
Dividend Ex-Date- Current Ratio3.99 EPS Y/Y TTM-18.67% Oper. Margin-266.01% RSI (14)20.82 Volatility7.24% 7.37%
Employees64 Debt/Eq0.02 Sales Y/Y TTM-40.09% Profit Margin-705.44% Recom1.29 Target Price9.83
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-4724.29% Payout- Rel Volume1.08 Prev Close1.56
Sales Surprise337.06% EPS Surprise-252.28% Sales Q/Q-47.58% EarningsFeb 27 BMO Avg Volume871.76K Price1.56
SMA20-20.14% SMA50-30.88% SMA200-16.47% Trades Volume944,789 Change0.00%
Date Action Analyst Rating Change Price Target Change
Dec-23-24Upgrade H.C. Wainwright Neutral → Buy $20
Nov-20-24Upgrade Cantor Fitzgerald Neutral → Overweight
Nov-19-24Upgrade Leerink Partners Market Perform → Outperform $2 → $7
Nov-19-24Upgrade Jefferies Hold → Buy $2 → $7
Nov-19-24Upgrade BTIG Research Neutral → Buy $8
Nov-18-24Upgrade Piper Sandler Neutral → Overweight $3 → $13
Jan-22-24Downgrade H.C. Wainwright Buy → Neutral
Nov-13-23Downgrade William Blair Outperform → Mkt Perform
Oct-03-23Initiated Evercore ISI Outperform $22
Dec-14-22Initiated Stifel Buy $29
Show Previous Ratings
Mar-04-25 07:00AM
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
(GlobeNewswire)
Feb-27-25 08:20AM
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
(Zacks) -7.14%
07:21AM
Aclaris: Q4 Earnings Snapshot
(Associated Press Finance)
06:59AM
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
(GlobeNewswire)
Feb-12-25 06:50AM
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
(GlobeNewswire)
04:01PM Loading…
Jan-30-25 04:01PM
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
(GlobeNewswire)
Jan-06-25 04:30PM
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(GlobeNewswire)
Dec-03-24 04:30PM
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
(GlobeNewswire)
Nov-26-24 04:30PM
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
(GlobeNewswire) -9.02% +5.23%
Nov-20-24 05:11AM
Aclaris Therapeutics upgraded to Buy from Hold at Jefferies
(TipRanks) -13.73%
Nov-19-24 09:30PM
Aclaris Therapeutics upgraded to Buy from Neutral at BTIG
(TipRanks) +46.18%
03:27PM
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
(Benzinga)
11:00AM
Aclaris Therapeutics secures global rights to Biosions antibodies
(Pharmaceutical Technology)
Nov-18-24 08:50AM
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
(PR Newswire) +53.17%
08:10AM
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
(GlobeNewswire)
08:10AM Loading…
08:10AM
Aclaris Therapeutics Announces $80 Million Private Placement
(GlobeNewswire)
Nov-06-24 08:05AM
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates
(Zacks)
07:07AM
Aclaris: Q3 Earnings Snapshot
(Associated Press Finance)
07:00AM
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
(GlobeNewswire)
Oct-09-24 07:02PM
Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc
(GuruFocus.com)
Sep-18-24 06:52AM
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial
(Clinical Trials Arena)
Sep-17-24 07:00AM
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
(GlobeNewswire)
Sep-10-24 07:00AM
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
(GlobeNewswire)
Aug-07-24 08:15AM
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
(Zacks)
07:20AM
Aclaris: Q2 Earnings Snapshot
(Associated Press Finance)
07:00AM
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
(GlobeNewswire)
Jul-25-24 09:40AM
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
(Zacks)
Jul-16-24 04:01PM
Aclaris Therapeutics Announces Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
(GlobeNewswire)
Jul-02-24 01:27PM
Hedge Fund and Insider Trading News: Bill Ackman, David Einhorn, Saba Capital Management, Segantii Capital Management, Two Sigma Advisors, Falcon Investment Management, Aclaris Therapeutics Inc (ACRS), GigaCloud Technology Inc (GCT), and More
(Insider Monkey)
Jun-06-24 07:00AM
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
(GlobeNewswire)
12:06PM Loading…
May-08-24 12:06PM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
(Insider Monkey) -8.96%
07:43AM
Q1 2024 Aclaris Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
04:06AM
Aclaris Therapeutics Inc (ACRS) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
(GuruFocus.com)
May-07-24 10:56PM
ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024
(InvestorPlace)
05:15PM
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
04:11PM
Aclaris: Q1 Earnings Snapshot
(Associated Press Finance)
04:01PM
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
(GlobeNewswire)
Apr-30-24 07:00AM
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
(GlobeNewswire)
Apr-23-24 08:00AM
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
(PR Newswire)
Apr-05-24 09:40AM
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
(Zacks)
Mar-20-24 09:40AM
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
(Zacks)
Mar-14-24 08:45AM
Biotech's Role in Addressing the Pancreatic Cancer Emergency
(PR Newswire) -8.00%
Mar-04-24 12:00PM
Aclaris (ACRS) Upgraded to Buy: Here's Why
(Zacks)
09:40AM
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
(Zacks)
Feb-27-24 09:35AM
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
(Zacks)
08:38AM
Aclaris: Q4 Earnings Snapshot
(Associated Press Finance)
07:00AM
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
(GlobeNewswire)
Feb-15-24 10:00AM
Will Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should Know
(Zacks)
Feb-13-24 09:40AM
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
(Zacks)
Jan-17-24 11:14AM
Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO
(Zacks)
Jan-16-24 07:00AM
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
(GlobeNewswire) +25.54%
Jan-10-24 07:00AM
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
(GlobeNewswire) -21.48%
Jan-04-24 09:40AM
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
(Zacks)
Dec-19-23 04:01PM
Aclaris Therapeutics Provides Corporate Update
(GlobeNewswire) +8.78% -8.33%
Dec-05-23 04:01PM
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
(GlobeNewswire)
Dec-04-23 09:35AM
Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks) +8.74%
Nov-16-23 09:35AM
Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)
(Zacks) +10.42%
Nov-14-23 10:57AM
Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study
(Zacks) +5.46%
Nov-13-23 07:17AM
UPDATE 1-Aclaris Therapeutics to stop development of rheumatoid arthritis drug
(Reuters) -86.44%
07:06AM
Aclaris Therapeutics to stop development of rheumatoid arthritis drug
(Reuters)
07:00AM
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
(GlobeNewswire)
Nov-06-23 08:03AM
Aclaris Therapeutics Inc (ACRS) Reports Q3 2023 Financial Results
(GuruFocus.com)
07:06AM
Aclaris: Q3 Earnings Snapshot
(Associated Press Finance)
07:00AM
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
(GlobeNewswire)
Oct-03-23 07:00AM
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
(GlobeNewswire)
Sep-20-23 07:00AM
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
(GlobeNewswire) -8.51%
Sep-18-23 07:00AM
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
(GlobeNewswire)
Sep-14-23 07:03PM
Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday
(Motley Fool) +5.54% -5.62%
Sep-08-23 05:06PM
Insider Buying: CFO Kevin Balthaser Acquires 9,490 Shares of Aclaris Therapeutics Inc
(GuruFocus.com)
Aug-10-23 06:07AM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
(Simply Wall St.)
Aug-08-23 08:40AM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analysts Just Slashed This Year's Revenue Estimates By 11%
(Simply Wall St.) -5.25%
Aug-07-23 08:15AM
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
(Zacks) -7.21%
07:10AM
Aclaris: Q2 Earnings Snapshot
(AP Finance)
07:00AM
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
(GlobeNewswire)
Aug-01-23 07:53AM
Investing in Aclaris Therapeutics (NASDAQ:ACRS) three years ago would have delivered you a 363% gain
(Simply Wall St.)
Jul-06-23 08:19AM
Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last?
(Zacks)
Jun-26-23 10:15AM
2 Low-Priced Stocks That Could Make You Richer
(Motley Fool)
Jun-13-23 06:30PM
Why Aclaris Therapeutics Topped the Market on Tuesday
(Motley Fool)
07:01AM
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)
(GlobeNewswire)
Jun-02-23 07:00AM
Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences
(GlobeNewswire)
May-18-23 01:50PM
Top Pharmaceutical Stocks for Q2 2023
(Investopedia)
May-10-23 06:04AM
Aclaris Therapeutics First Quarter 2023 Earnings: Beats Expectations
(Simply Wall St.)
May-08-23 11:55PM
Q1 2023 Aclaris Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) -6.46%
08:15AM
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
07:08AM
Aclaris: Q1 Earnings Snapshot
(AP Finance)
07:00AM
Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update
(GlobeNewswire)
May-05-23 06:49AM
What Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) P/S Is Not Telling You
(Simply Wall St.)
May-02-23 07:01AM
Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023
(GlobeNewswire)
Apr-27-23 04:35AM
Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock?
(Zacks)
Apr-24-23 02:37PM
3 Biotech Stocks to Sell Before Theyre 6 Feet Under
(InvestorPlace)
Apr-04-23 07:40AM
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
(Simply Wall St.)
Mar-27-23 07:00AM
Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
(GlobeNewswire)
Mar-10-23 11:34AM
Lab Notes: Fox Chase Cancer Center researcher gets $1M grant; NRx raises funds
(American City Business Journals)
Mar-06-23 03:59PM
As Focus Shifts From Hidradenitis Suppurativa, Analyst Seems Bullish On Aclaris
(Benzinga) -44.68%
02:32PM
These 2 Biotech Stocks Made Big Monday Moves
(Motley Fool)
01:03PM
Why Aclaris Therapeutics Stock Is Plunging Today
(Benzinga)
11:50AM
Why Aclaris Therapeutics Is Crashing Today
(Motley Fool)
07:00AM
Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa
(GlobeNewswire)
Feb-23-23 08:35AM
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
(Zacks)
07:00AM
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
(GlobeNewswire)
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walker NealINTERIM CEODec 04 '24Option Exercise1.52118,840180,6371,501,973Dec 06 04:15 PM
Mehra AnandDirectorNov 19 '24Buy2.25666,6661,499,998710,030Nov 20 04:20 PM
Walker NealINTERIM PRESIDENT AND CEOAug 09 '24Option Exercise0.7243,54831,3551,356,153Aug 13 04:15 PM
Leonard Braden Michael10% OwnerAug 05 '24Buy1.24206,025256,35714,250,000Aug 05 03:57 PM
Leonard Braden Michael10% OwnerAug 02 '24Buy1.29167,544216,40014,043,975Aug 05 03:57 PM
Leonard Braden Michael10% OwnerJul 30 '24Buy1.30173,730226,37013,776,421Jul 31 04:10 PM
Leonard Braden Michael10% OwnerJul 31 '24Buy1.33100,000132,64013,876,421Jul 31 04:10 PM
Leonard Braden Michael10% OwnerJul 18 '24Buy1.30130,317169,55513,578,286Jul 22 04:03 PM
Leonard Braden Michael10% OwnerJul 22 '24Buy1.3317,71623,55713,602,691Jul 22 04:03 PM
Leonard Braden Michael10% OwnerJul 19 '24Buy1.306,6898,69613,584,975Jul 22 04:03 PM
Leonard Braden Michael10% OwnerJul 03 '24Buy1.16143,288166,07113,324,952Jul 05 02:46 PM
Leonard Braden Michael10% OwnerJul 05 '24Buy1.15123,017141,33413,447,969Jul 05 02:46 PM
Leonard Braden Michael10% OwnerJul 02 '24Buy1.1486,09298,48913,181,664Jul 05 02:46 PM
Leonard Braden Michael10% OwnerJun 28 '24Buy1.121,201,0001,348,55912,988,134Jul 01 01:39 PM
Leonard Braden Michael10% OwnerJun 27 '24Buy1.15235,000271,33111,787,134Jul 01 01:39 PM
Leonard Braden Michael10% OwnerJul 01 '24Buy1.14107,434122,18513,095,572Jul 01 01:39 PM
Leonard Braden Michael10% OwnerJun 14 '24Buy1.17345,000402,20111,352,134Jun 18 04:04 PM
Leonard Braden Michael10% OwnerJun 17 '24Buy1.13150,000169,50011,502,134Jun 18 04:04 PM
Leonard Braden Michael10% OwnerJun 18 '24Buy1.1350,00056,50511,552,134Jun 18 04:04 PM
Leonard Braden Michael10% OwnerJun 11 '24Buy1.081,000,0001,080,00010,395,934Jun 13 06:04 PM
Leonard Braden Michael10% OwnerJun 13 '24Buy1.15528,621607,75711,007,134Jun 13 06:04 PM
Leonard Braden Michael10% OwnerJun 12 '24Buy1.1482,57994,14010,478,513Jun 13 06:04 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.